Sei Shu1,2, Makoto Iimori3, Ryota Nakanishi1, Tomoko Jogo1, Hiroshi Saeki1, Eiji Oki4, Yoshihiko Maehara1,5. 1. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Kyushu University, Fukuoka, Japan. 2. Product Research Department, Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan. 3. Department of Molecular Cancer Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Kyushu University, Fukuoka, Japan. 4. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Kyushu University, Fukuoka, Japan okieiji@surg2.med.kyushu-u.ac.jp. 5. Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan.
Abstract
BACKGROUND: It is essential to establish a strategy for second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer; however, HER2 expression status after chemotherapy treatment is not routinely determined. MATERIALS AND METHODS: We analyzed 25 cases of gastric cancer that received preoperative chemotherapy and selected the six pre-treatment samples that were HER2-positive. Pre- and post-treatment tumor samples were examined for HER2 expression, and for HER2, epidermal growth factor receptor (EGFR), and hepatocyte growth factor receptor (MET) gene amplification. RESULTS: Three patients had been treated with trastuzumab plus chemotherapy, and three patients with cytotoxic chemotherapy alone. Only one case that had an initial HER2 score of 3+ and had received trastuzumab plus chemotherapy remained HER2-positive after treatment. Decrease or loss of HER2 expression and amplification was observed in the other five patients. Amplification of EGFR or MET was not observed in any pre- or post-treatment specimens. CONCLUSION: Our data suggest that trastuzumab plus chemotherapy or chemotherapy alone may induce loss of HER2 positivity. Copyright
BACKGROUND: It is essential to establish a strategy for second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer; however, HER2 expression status after chemotherapy treatment is not routinely determined. MATERIALS AND METHODS: We analyzed 25 cases of gastric cancer that received preoperative chemotherapy and selected the six pre-treatment samples that were HER2-positive. Pre- and post-treatment tumor samples were examined for HER2 expression, and for HER2, epidermal growth factor receptor (EGFR), and hepatocyte growth factor receptor (MET) gene amplification. RESULTS: Three patients had been treated with trastuzumab plus chemotherapy, and three patients with cytotoxic chemotherapy alone. Only one case that had an initial HER2 score of 3+ and had received trastuzumab plus chemotherapy remained HER2-positive after treatment. Decrease or loss of HER2 expression and amplification was observed in the other five patients. Amplification of EGFR or MET was not observed in any pre- or post-treatment specimens. CONCLUSION: Our data suggest that trastuzumab plus chemotherapy or chemotherapy alone may induce loss of HER2 positivity. Copyright
Authors: Kab Choong Kim; Young Wha Koh; Heung-Moon Chang; Tae Hwan Kim; Jeong Hwan Yook; Byung Sik Kim; Se Jin Jang; Young Soo Park Journal: Ann Surg Oncol Date: 2011-04-06 Impact factor: 5.344
Authors: Elizabeth A Mittendorf; Yun Wu; Maurizio Scaltriti; Funda Meric-Bernstam; Kelly K Hunt; Shaheenah Dawood; Francisco J Esteva; Aman U Buzdar; Huiqin Chen; Sameena Eksambi; Gabriel N Hortobagyi; Jose Baselga; Ana M Gonzalez-Angulo Journal: Clin Cancer Res Date: 2009-11-17 Impact factor: 12.531
Authors: M Hofmann; O Stoss; D Shi; R Büttner; M van de Vijver; W Kim; A Ochiai; J Rüschoff; T Henkel Journal: Histopathology Date: 2008-04-18 Impact factor: 5.087
Authors: M Varella-Garcia; J Diebold; D A Eberhard; K Geenen; A Hirschmann; M Kockx; I Nagelmeier; J Rüschoff; M Schmitt; S Arbogast; F Cappuzzo Journal: J Clin Pathol Date: 2009-11 Impact factor: 3.411
Authors: Sebastian Schade; Ute Koenig; Ardian Mekolli; Jochen Gaedcke; Albrecht Neesse; Johanna Reinecke; Marius Brunner; Ali Seif Amir Hosseini; Julia Kitz; Philipp Stroebel; Joachim Lotz; Michael Ghadimi; Volker Ellenrieder; Alexander Koenig Journal: Case Rep Gastroenterol Date: 2022-02-17